2025 HFM Symposium - Managing Hyperkalemia in Heart Failure: Implementing Strategies to Reduce Patient Risk
Jersey Desk/10300926

HAZLET, N.J. - JerseyDesk -- In this symposium, attendees will be provided with best practices by a multidisciplinary faculty on the prevention of hyperkalemia, identification of patients at risk for hyperkalemia, the importance of maintaining HF patients on RAASi's and preferably at target doses, recent clinical evidence with novel potassium binders, and strategies for effective communication with patients.

Click here for more information

CHAIR

Akshay Desai, MD, MPH
Professor of Medicine
Harvard Medical School
Cardiovascular Division
Brigham and Women's Hospital
Boston, Massachusetts

FACULTY

Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC

More on Jersey Desk

• DominoZee Drops a Rebel-Made Apparel Line Redefining Modern Street Culture
• Kentucky Judges Ignore Evidence, Prolong Father's Ordeal in Baseless Case
• Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor
• Rigani Press Announces Barnes & Noble Book Signing for Dr. S. Yin Ho's Groundbreaking Book
• Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform

Associate Chief Nursing Officer--Research and Innovation
Clinical Nurse Specialist--Kaufman Center for Heart Failure
Cleveland Clinic
Cleveland, Ohio

Stephen Greene, MD
Associate Professor of Medicine
Duke University School of Medicine
Duke Clinical Research Institute
Durham, North Carolina

Robert Page, PharmD, MSPH, BCPS, BCGP
Professor, Departments of Clinical Pharmacy and Physical Medicine
Skaggs School of Pharmacy and Pharmaceutical Sciences
CU Anschutz
Aurora, Colorado

Educational Objectives
- Identify HF patients at risk for hyperkalemia
- Explain the relationship between down-titration or discontinuation of RAASi therapy and clinical outcomes
- Describe the clinical profi les of novel potassium binders
- Interpret the evidence with novel potassium binders for lowering potassium levels and reducing the risk of down-titration of mineralocorticoid receptor antagonist (MRA) therapy

Target Audience
This educational activity is intended for clinicians who manage patients with heart failure.

More on Jersey Desk

• IODefi Introduces New Web3 Infrastructure Framework as XRP Ledger Development Gains Global Attention
• Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
• EnergyStrat Launches Global LNG Risk Outlook 2025–2030
• Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
• MDC Design Center Expands Kitchen and Bath Remodeling Solutions in Cherry Hill for 2026

Educational Grant
Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.

Accreditation and Credit Designation Statements
Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia, LLC designates this live activity for a maximum of 1.0 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.